ResearcherThird Affiliated Hospital of Guangzhou Medical UniversityNo recent work listed
Pengke Yan
Matched on ORCID iD 0000-0002-8356-2986; OpenAlex author ID A5023251132.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 2 (first author 0, last author 2)
- Pancreatic cancer trials
- 0
- Pancreatic cancer grants
- 0
- Labs led
- 1
- Collaborators
- 2
2023: 2 papers
Papers 2
- Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis through stromal modulation. Last author DOI 10.1016/j.ijpharm.2023.123316↗
- Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pan… Last author DOI 10.1039/d3bm01118f↗
Closest collaborators
The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Wenting Zhu · 2 shared papers, 2023
- Paper Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis throug… DOI 10.1016/j.ijpharm.2023.123316↗
- Paper Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the ef… DOI 10.1039/d3bm01118f↗
- Hang Yu · 2 shared papers, 2023
- Paper Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis throug… DOI 10.1016/j.ijpharm.2023.123316↗
- Paper Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the ef… DOI 10.1039/d3bm01118f↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.